[Federal Register Volume 80, Number 235 (Tuesday, December 8, 2015)]
[Notices]
[Pages 76279-76280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30861]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing this notice to 
announce a Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: Thursday, January 7, 2016, from 9:00 a.m. to 1:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 
5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. Fax: 
(703) 681-1940. Email Address: [email protected].

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act of 1972 (Title 5, 
United States Code (U.S.C.), Appendix, as amended) and the Government 
in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended).
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of Defense Health Agency, by the 
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

Meeting Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Attention Deficit Hyperactivity Disorder (ADHD)--Stimulants
    b. Antirheumatic Drugs--Methotrexate Injectable
    c. Gastrointestinal -2 Agents--Miscellaneous
    d. Acne--Isotretinoins
5. Designated Newly Approved Drugs in Already-Reviewed Classes
6. Designated Newly FDA Approved Drugs
7. Pertinent Utilization Management Issues
8. Panel Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 7:45 a.m. to 9:00 a.m. 
to discuss administrative matters of the

[[Page 76280]]

Panel. The Administrative Work Meeting will be held at the Naval 
Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. 
Pursuant to 41 CFR 102-3.160, the Administrative Work Meeting will be 
closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at http://facadatabase.gov/. Written 
statements that do not pertain to the scheduled meeting of the Panel 
may be submitted at any time. However, if individual comments pertain 
to a specific topic being discussed at a planned meeting, then these 
statements must be submitted no later than 5 business days prior to the 
meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: December 3, 2015.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2015-30861 Filed 12-7-15; 8:45 am]
 BILLING CODE 5001-06-P